Pilot Study of Ruboxistaurin Showed Favorable Effects on Kidney Damage

Eli Lilly and Company has announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with Type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

Data showed that in patients being treated with angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), or both, ruboxistaurin significantly reduced albuminuria (an indicator of diabetic kidney damage) by 24 percent, compared to a nonsignificant 9 percent reduction in patients taking placebo.